ST. LOUIS — The number of plaintiffs claiming Monsanto's Roundup weed killer caused their cancer continues to climb, as settlement talks have slowed because of the Covid-19 pandemic, Bayer said Monday in reporting its first-quarter financial results.
Bayer, which acquired Roundup in its $63 billion acquisition of St. Louis-based Monsanto Co. in 2018, also raised concerns about liquidity due to a recession and a possible settlement. The German company said it would consider only a “financially reasonable” settlement that resolves the potential for future claims, The Wall Street Journal reported.
“Against the background of a looming recession and looking at, in part, considerable liquidity challenges, this applies now more than ever,” the company said.
